In a phase I clinical investigation, by day 28 following therapy with tandem bispecific anti-CD20, anti-CD19 (LV20.19) CAR T cells, 18 (82%) of the R/R B-ALL patients experienced an overall response, with 14 (64%) achieving a CR, and 4 (18%) having a partial response (PR). Here, CD19 is linked to acute lymphoblastic leukemia.